- Trials with a EudraCT protocol (39)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (3)
39 result(s) found for: Iga Nephropathy.
Displaying page 1 of 2.
EudraCT Number: 2016-004507-31 | Sponsor Protocol Number: P140931 | Start Date*: 2017-01-27 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002200-40 | Sponsor Protocol Number: CLNP023A2002B | Start Date*: 2021-08-05 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A multicenter rollover extension program (REP) to evaluate the long-term safety and tolerability of open label iptacopan in adult participants with primary IgA nephropathy who have completed a Nova... | |||||||||||||
Medical condition: IgA Nephropathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) BE (Trial now transitioned) DK (Trial now transitioned) CZ (Trial now transitioned) NL (Ongoing) NO (Trial now transitioned) IT (Ongoing) FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002345-64 | Sponsor Protocol Number: 181501 | Start Date*: 2015-11-12 | |||||||||||
Sponsor Name:Baxalta Innovations GmbH | |||||||||||||
Full Title: A Phase 2 Study to Assess the Efficacy and Safety of Intravenous Infusion with Human Soluble Recombinant Fc-gamma Receptor IIB (SM101/BAX 1810) in Subjects with Immunoglobulin A Nephropathy (IgAN) | |||||||||||||
Medical condition: IgA Nephropathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-005526-17 | Sponsor Protocol Number: 417-201-00012 | Start Date*: 2022-12-09 | |||||||||||
Sponsor Name:Otsuka Pharmaceutical Development and Commercialization, Inc. | |||||||||||||
Full Title: A Phase 2/3, Multicenter, Open-label Trial to Evaluate the Long-term Safety, Tolerability, and Efficacy of Sibeprenlimab Administered Subcutaneously in Subjects with Immunoglobulin A Nephropathy | |||||||||||||
Medical condition: Immunoglobulin A Nephropathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002262-31 | Sponsor Protocol Number: MS700461-0035 | Start Date*: 2017-03-17 | ||||||||||||||||
Sponsor Name:Merck KGaA | ||||||||||||||||||
Full Title: A Phase II Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in IgA Nephropathy | ||||||||||||||||||
Medical condition: IgA Nephropathy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-001365-26 | Sponsor Protocol Number: AN-IGN3321 | Start Date*: 2014-08-21 | |||||||||||
Sponsor Name:Anthera Pharmaceuticals, Inc | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects with IgA Nephropathy | |||||||||||||
Medical condition: IgA Nephropathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) DE (Completed) IT (Prematurely Ended) HU (Completed) SE (Ongoing) ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004892-41 | Sponsor Protocol Number: VT-001-0050 | Start Date*: 2021-07-13 | |||||||||||
Sponsor Name:Vera Therapeutics, Inc. | |||||||||||||
Full Title: A Phase IIb Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of Atacicept in Subjects with IgA Nephropathy (IgAN) | |||||||||||||
Medical condition: IgA Nephropathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Ongoing) CZ (Trial now transitioned) DE (Trial now transitioned) GR (Trial now transitioned) PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001923-11 | Sponsor Protocol Number: Nef-202 | Start Date*: 2012-10-17 | |||||||||||
Sponsor Name:Pharmalink AB | |||||||||||||
Full Title: A Multicentre, Interventional Treatment, Randomised, Double-Blind, Single Group Assignment, Placebo Controlled Study to Evaluate the Efficacy and Safety of Two Different Doses of Nefecon® in Primar... | |||||||||||||
Medical condition: Primary IgA nephropathy patients at risk of developing end stage renal disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) CZ (Completed) DE (Completed) BE (Completed) SE (Completed) DK (Completed) IT (Completed) GB (Completed) NL (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003308-14 | Sponsor Protocol Number: Nef-301OLE | Start Date*: 2020-10-21 | |||||||||||
Sponsor Name:Calliditas Therapeutics AB | |||||||||||||
Full Title: An Open-Label Extension (OLE) Study to Evaluate the Efficacy and Safety of Nefecon Treatment in Patients With IgA Nephropathy Who Have Completed Study Nef-301 | |||||||||||||
Medical condition: Primary IgA nephropathy patients at risk of developing end stage renal disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) SE (Completed) PL (Completed) BE (Completed) FR (Ongoing) GB (GB - no longer in EU/EEA) GR (Completed) FI (Completed) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005054-19 | Sponsor Protocol Number: MOR202C206 | Start Date*: 2021-07-28 | |||||||||||
Sponsor Name:Human Immunology Biosciences, Inc | |||||||||||||
Full Title: A Double Blind, Randomized, Placebo-Controlled, Multicenter Phase IIa, Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab in IgA Nephropathy - IGNAZ | |||||||||||||
Medical condition: IgA Nephropathy (IgAN) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Ongoing) BG (Ongoing) DE (Ongoing) BE (Ongoing) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000075-33 | Sponsor Protocol Number: OMS721-IGA-001 | Start Date*: 2018-06-07 |
Sponsor Name:Omeros Corporation | ||
Full Title: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS – IGAN) | ||
Medical condition: IgA nephropathy (IgAN) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Ongoing) CZ (Prematurely Ended) SK (Prematurely Ended) LT (Prematurely Ended) SE (Completed) ES (Prematurely Ended) BE (Completed) AT (Prematurely Ended) PL (Ongoing) BG (Completed) GB (GB - no longer in EU/EEA) DE (Completed) IT (Prematurely Ended) GR (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2014-003402-33 | Sponsor Protocol Number: CL005_168 | Start Date*: 2015-02-09 | |||||||||||
Sponsor Name:ChemoCentryx, Inc. | |||||||||||||
Full Title: An open-label phase 2 study to evaluate the safety and efficacy of CCX168 in subjects with IgA Nephropathy on stable RAAS blockade. | |||||||||||||
Medical condition: IgAN is reported as the most common glomerulonephritis worldwide. It is associated with a wide spectrum of disease severity and rate of progression of renal failure. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-016003-26 | Sponsor Protocol Number: 1.0 | Start Date*: 2010-05-06 | ||||||||||||||||
Sponsor Name:UHB NHS Foundation Trust | ||||||||||||||||||
Full Title: RANDOMISED PILOT TRIAL OF MYFORTIC FOR THE TREATMENT OF PRIMARY PROTEINURIC GLOMERULONEPHRITIS. | ||||||||||||||||||
Medical condition: Primary Proteinuric Glomeruolnephritis Focal segmental glomeruloscerosis and IgA nephropathy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005855-19 | Sponsor Protocol Number: BCX9930-211 | Start Date*: 2021-10-11 | |||||||||||||||||||||
Sponsor Name:BioCryst Pharmaceuticals Inc | |||||||||||||||||||||||
Full Title: An Open-Label, Safety, Tolerability, and Proof-of-Concept Study of Oral BCX9930 Therapy in Subjects with Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy, or Primary Membranous Nephropathy | |||||||||||||||||||||||
Medical condition: complement 3 glomerulopathy immunoglobulin A nephropathy primary membranous nephropathy | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: ES (Prematurely Ended) IT (Prematurely Ended) HU (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-001537-13 | Sponsor Protocol Number: ALXN1210-NEPH-202 | Start Date*: 2021-03-25 | ||||||||||||||||
Sponsor Name:Alexion Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants With Proliferative Lupus Nephritis (LN) or Immunoglobulin A Ne... | ||||||||||||||||||
Medical condition: Lupus Nephritis (LN) Immunoglobulin A Nephropathy (IgAN) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) SE (Trial now transitioned) ES (Ongoing) IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004902-16 | Sponsor Protocol Number: Nef-301 | Start Date*: 2018-06-04 | |||||||||||
Sponsor Name:Calliditas Therapeutics AB | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients with Primary IgA Nephropathy at Risk of Progressing to End-Stage Renal Disease (NefIgArd). | |||||||||||||
Medical condition: Primary IgA nephropathy patients at risk of developing end stage renal disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) SE (Completed) BE (Completed) FI (Completed) ES (Completed) GB (GB - no longer in EU/EEA) PL (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001426-22 | Sponsor Protocol Number: ALXN2050-NEPH-201 | Start Date*: 2022-05-30 | ||||||||||||||||
Sponsor Name:Alexion Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants with Proliferative Lupus Nephritis (LN) or Immunogl... | ||||||||||||||||||
Medical condition: Lupus Nephritis (LN) Immunoglobulin A Nephropathy (IgAN) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Trial now transitioned) IT (Ongoing) ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004366-10 | Sponsor Protocol Number: 0642 | Start Date*: 2019-05-24 | |||||||||||
Sponsor Name:University of Leicester | |||||||||||||
Full Title: A Phase 2 Placebo-controlled Double Blinded Study to Assess the Efficacy and Safety of Belimumab in Subjects with Immunoglobulin A Nephropathy (IgAN) | |||||||||||||
Medical condition: Immunoglobulin A (IgA) nephropathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004605-41 | Sponsor Protocol Number: 021IGAN17001 | Start Date*: 2018-10-04 | |||||||||||
Sponsor Name:Retrophin, Inc. | |||||||||||||
Full Title: A Randomized, Multicenter, Double-blind, Parallel-group, Active-control Study of the Efficacy and Safety of Sparsentan for the Treatment of Immunoglobulin A Nephropathy | |||||||||||||
Medical condition: Immunoglobulin A Nephropathy (IgAN) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Ongoing) LT (Ongoing) BE (Ongoing) CZ (Ongoing) ES (Ongoing) EE (Ongoing) PT (Ongoing) PL (Ongoing) HR (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000621-27 | Sponsor Protocol Number: RTRX-RE021-201 | Start Date*: 2022-10-20 | |||||||||||||||||||||||||||||||
Sponsor Name:Travere Therapeutics, Inc. | |||||||||||||||||||||||||||||||||
Full Title: A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Treatment in Pediatric Subjects with Selected Proteinuric Glomerular Diseases (E... | |||||||||||||||||||||||||||||||||
Medical condition: Proteinuric glomerular diseases including: •Focal segmental glomerulosclerosis (FSGS) •Minimal change disease (MCD) •Immunoglobulin A nephropathy (IgAN) •Immunoglobulin A vasculitis (IgAV) •Al... | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: FR (Completed) ES (Temporarily Halted) SE (Restarted) PL (Ongoing) DE (Restarted) IT (Ongoing) NL (Restarted) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.